Nicole R. Zane

Nicole R. Zane

Auto-generated profile, based on publicly available information

Nicole R. Zane

Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy at The University of North Carolina at Chapel Hill, Chapel Hill

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 November 2017 in Pediatric Research
Verified
Journal Article
Open access
PDF file
NZNicole R Zane
Nicole R Zane
YCYao Chen
Yao Chen
MWMichael Zhuo Wang
Michael Zhuo Wang
DTDhiren R Thakker
Dhiren R Thakker
Background Age-dependent differences in pharmacokinetics exist for metabolically cleared medications. Differential contributions in the cytochrome P450 3A (CYP3A), CYP2C, and flavin-containing monooxygenases (FMOs) families have an important role in the metabolic clearance of a large number of drugs administered to children. Methods Unlike previous semiquantitative characterization of age-dependent changes in the expression of genes and proteins (western blot analysis), this study quantifies both gene and absolute protein expression in the same fetal, pediatric, and adult hepatic tissue. Expression was then correlated with the corresponding functional activities in the same samples. Results CYP3A and FMO families showed a distinct switch from fetal (CYP3A7 and FMO1) to adult isoforms (CYP3A4 and FMO3) at birth, whereas CYP2C9 showed a linear maturation from birth into adulthood. In contrast, analysis of CYP2C19 revealed higher expression and catalytic efficiency in pediatric samples compared with that in fetal and adult samples. Further, CYP3A and FMO enzymes exhibited an unexpectedly higher functional activity in fetal samples not entirely explained by protein expression. Conclusion These surprising findings suggest that CYP and FMO enzymes may encounter development-related differences in their microenvironments that can influence the enzyme activity in addition to protein expression levels.

1 July 2016 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
YCYao Chen
Yao Chen
NZNicole R. Zane
Nicole R. Zane
DTDhiren R. Thakker
Dhiren R. Thakker
MWMichael Zhuo Wang
Michael Zhuo Wang
Flavin-containing monooxygenases (FMOs) have a significant role in the metabolism of small molecule pharmaceuticals. Among the five human FMOs, FMO1, FMO3, and FMO5 are the most relevant to hepatic drug metabolism. Although age-dependent hepatic protein expression, based on immunoquantification, has been reported previously for FMO1 and FMO3, there is very little information on hepatic FMO5 protein expression. To overcome the limitations of immunoquantification, an ultra-performance liquid chromatography (UPLC)-multiple reaction monitoring (MRM)-based targeted quantitative proteomic method was developed and optimized for the quantification of FMO1, FMO3, and FMO5 in human liver microsomes (HLM). A post-in silico product ion screening process was incorporated to verify LC-MRM detection of potential signature peptides before their synthesis. The developed method was validated by correlating marker substrate activity and protein expression in a panel of adult individual donor HLM (age 39–67 years). The mean (range) protein expression of FMO3 and FMO5 was 46 (26–65) pmol/mg HLM protein and 27 (11.5–49) pmol/mg HLM protein, respectively. To demonstrate quantification of FMO1, a panel of fetal individual donor HLM (gestational age 14–20 weeks) was analyzed. The mean (range) FMO1 protein expression was 7.0 (4.9–9.7) pmol/mg HLM protein. Furthermore, the ontogenetic protein expression of FMO5 was evaluated in fetal, pediatric, and adult HLM. The quantification of FMO proteins also was compared using two different calibration standards, recombinant proteins versus synthetic signature peptides, to assess the ratio between holoprotein versus total protein. In conclusion, a UPLC-MRM-based targeted quantitative proteomic method has been developed for the quantification of FMO enzymes in HLM.

1 July 2017 in Pediatric Critical Care Medicine
Verified
Journal Article
Closed access
NZNicole R. Zane
Nicole R. Zane
MRMichael D. Reedy
Michael D. Reedy
MGMarc R. Gastonguay
Marc R. Gastonguay
AHAdam S. Himebauch
Adam S. Himebauch
EREvan Z. Ramsey
Evan Z. Ramsey
AZAthena F. Md Zuppa
Athena F. Md Zuppa
Objectives: Limited data exist on the effects of therapeutic hypothermia on renal function and pharmacokinetics in pediatric patients after cardiac arrest. The objective was to describe the differences in vancomycin disposition in pediatric patients following cardiac arrest treated with either therapeutic hypothermia or normothermia using population pharmacokinetic modeling. Design: Single-center, retrospective cohort study. Setting: A tertiary care hospital pediatric and cardiac ICU. Patients: Fifty-two pediatric patients (30 d to 17 yr old) who experienced a cardiac arrest, received vancomycin, and were treated with therapeutic hypothermia (32–34°C) or normothermia (36.3–37.6°C) between January 1, 2010, and September 30, 2014, were reviewed. Interventions: None. Measurements and Main Results: A two-compartment model with linear elimination, weight effects on clearance, intercompartmental clearance (Q), central volume of distribution (V1), and peripheral volume of distribution (V2) adequately described the data despite high variability due to the small sample size. The typical value of clearance in this study was 4.48 L/hr (0.19 L/hr/kg0.75) for a normothermic patient weighing 70 kg and a glomerular filtration rate of 90 mL/min/1.73 m2. Patients treated with normothermia but with reduced or poor renal function (≤ 90 mL/min/1.73 m2) had up to an 80% reduction in vancomycin clearance compared to those with normal renal function (90–140 mL/min/1.73 m2). Patients with normal renal function but treated with therapeutic hypothermia versus normothermia experienced up to 25% reduction in vancomycin clearance. Patients treated with therapeutic hypothermia and with poor renal function experienced up to an 84% reduction in vancomycin clearance. Conclusions: Patients receiving hypothermia and/or with decreased renal function had lower vancomycin clearances based on a retrospectively fitted two-compartment model in children who experience cardiac arrest.

12 May 2016 in Journal of Perinatology
Verified
Journal Article
Open access
PDF file
NTN Thakkar
N Thakkar
DGD Gonzalez
D Gonzalez
MCM Cohen-Wolkowiez
M Cohen-Wolkowiez
MMM M Massaro
M M Massaro
JBJ Bernhardt
J Bernhardt
MLM M Laughon
M M Laughon
The objective of this study is to assess sildenafil and N-desmethyl sildenafil (DMS) exposure in infants receiving sildenafil for the treatment of pulmonary hypertension (PH). Data were collected from six infants receiving sildenafil for the treatment of PH and plasma samples were collected at the time of routine laboratory blood draws. The echocardiography results were assessed for improvement in right ventricular (RV) hypertension following sildenafil treatment. The median (range) sildenafil and DMS concentrations were 27.4 ng ml−1 (2.6 to 434.0) and 105.5 ng ml−1 (3.6 to 314.0), respectively. The median metabolite-to-parent ratio was higher in infants receiving co-medications that can induce cytochrome P450 (CYP) enzymes (5.2 vs 0.7). The echocardiography results showed improvement in RV hypertension for the majority of infants (5/6). The concentrations of sildenafil and DMS were within the previously observed ranges. Our results suggest that caution may be warranted when CYP-related co-medications are administered during sildenafil treatment for PH.